Effects of RNAi-mediated cathepsin L gene silencing on bionomics of hepatoma carcinoma cells

African Journal of Biotechnology

Volumn 9, Issue 31, 2010, Pages 5013-5021

  Jin, Yun ^a   Luo, Ding ^a   Hua, Aijun ^b   Dong, Jiahong ^b  

^a KUNMING GENERAL HOSPITAL   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cathepsin L.; Liver cancer; RNA interference

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CATHEPSIN L; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; GROWTH INHIBITION; HEPATOMA CARCINOMA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

EID: 77956124243     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Akhtar S, Benter I (2007). Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliv. Rev. 59: 164-182.
2. Caserman S, Kenig S, Sloane Bf, Lah TT (2006). Cathepsin L splice variants in human breast cell lines. Biol Chem. 387: 629-634.
3. Colella R, Jackson T, Goodwyn E (2004). Matrigel invasion by the prostate cancer cell lines, PC3 and DU145, and Cathepsin L+B activity. Biotechnol. Histochem. 79: 121-127.
4. Colmenares SU, Buker SM, Buhler M (2007).Coupling of double-stranded RNA synthesis and siRNA generation in fission yeast RNAi. Mol Cell, 27: 449-461.
5. Fortenberry YM, Brandal S, Bialas RC, Church FC (2010). Protein C inhibitor regulates both cathepsin L activity and cell-mediated tumor cell migration. Biochim. Biophys. Acta. 1800: 580-590
6. Hashimoto Y, Kondo C, Kojima T (2006). Significance of 32-kDa Cathepsin L secreted from cancer cells. Cancer Biother. Radiopharm. 21: 217-224.
7. Holmes RJ, Cohen PE (2007). Small RNAs and RNAi pathways in meiotic prophase I. Chromosome Res. 15: 653-665.
8. Kishore Kumar GD, Chavarria GE, Charlton-Sevcik AK, Arispe WM, Macdonough MT, Strecker TE, Chen SE, Siim BG, Chaplin DJ, Trawick ML, Pinney KG (2010). Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorg. Med. Chem. Lett. 20: 1415-1419.
9. Krueger U, Bergauer T, Kaufmann B (2007). Insights into effective RNAi gained from large-scale siRNA validation screening. Oligonucleotides, 17: 237-250.
10. Lu DD, Zhang XR, Cao XR (2004). Expression of TN4 gene and its role in human hepatocarcinogenesis from Qidong, a liver cancer risk area. Chin. Med. J. (Engl), 117: 440-444.
11. Matsui K, Sasaki Y, Komatsu T (2007). RNAi gene silencing using cerasome as a viral-size siRNA-carrier free from fusion and cross-linking. Bioorg. Med. Chem. Lett. 17: 3935-3938.
12. Stabuc B, Mrevlje Z, Markovic J, Stabuc-Silih M (2006). Expression and prognostic significance of Cathepsin L in early cutaneous malignant melanoma. Neoplasma, 53: 259-262.